Neko Health Raises $700M Series C Led by Lightspeed Venture Partners
Key Points
- Neko Health raised $700 million in Series C funding led by Lightspeed Venture Partners and O.G. Venture Partners.
- The startup has scanned over 100,000 people and has 350,000+ on its waitlist; it's preparing to open its first U.S. location in New York.
- Neko Health's technology combines proprietary body scanning with bloodwork and can integrate Apple Health data for personalized health assessments.
The startup currently operates locations in the United Kingdom and Sweden and is preparing for its first U.S. expansion with a location planned in New York. According to the company, more than 100,000 people have already undergone scans, while an additional 350,000 have registered for the waitlist or set appointments. These figures suggest substantial market demand ahead of the U.S. launch.
Validation From Early Users and Market Expansion
Read Next
Meta Reports Q2 Earnings Amid AI Investment Concerns
7 days ago
Nvidia Launches Cybersecurity Initiative for Open-Source AI Defense
8 days ago
Neko Health has garnered attention from prominent tech figures. Calm founder Alex Tew posted on X that a Neko Health scan identified a malignant mole on his back, which he subsequently had removed. "I'm grateful to Neko for helping me discover this – I'm not sure how I would have otherwise," Tew wrote, providing real-world validation of the technology's diagnostic capabilities.
The company operates in a growing market segment. MidJourney, the AI image and video creation company, is developing a competing body-scanning offering that it plans to integrate into a spa experience featuring hot tubs and saunas, scheduled to open in San Francisco in 2027. However, Neko Health's existing user base and international footprint position it ahead in near-term market development.
Related coverage: Meta Reports Q2 Earnings Amid AI Investment Concerns
The funding enables Neko Health to accelerate its U.S. market entry, expand its clinical capabilities, and continue refining its scanning technology. The company's ability to combine hardware innovation with health data integration and clinical assessment represents a distinct competitive approach in the consumer health technology space.
Neko Health's rapid capital accumulation—$960 million in two funding rounds within six months—indicates investor appetite for health-tech companies offering tangible diagnostic value and differentiated technology. The company's waitlist of 350,000 people provides substantial runway for revenue growth across its UK, Swedish, and incoming U.S. markets.
Why this matters: If you're interested in health monitoring or preventive medicine, Neko Health's expansion into the U.S. means faster access to body-scanning assessments without traveling internationally. For investors tracking health-tech trends, the $700 million raise signals confidence in full-body diagnostic scanning as a viable consumer health service, potentially validating the broader shift toward personalized preventive health assessment.
What This Means
Neko Health's $700 million Series C positions it to dominate consumer body-scanning diagnostics before competitors like MidJourney launch. The New York location will serve as a beachhead for U.S. expansion, with the 350,000-person waitlist providing immediate revenue. Expect the company to scale to 10+ U.S. locations within 24 months and potentially achieve unicorn status through acquisition or IPO within 3-5 years as health systems integrate its technology.
Sources: AP, Reuters, ESPN, Bloomberg, BBC and other international news outlets.
Disclaimer: This article is for informational purposes only. Content is based on publicly available news sources.
